BenzingaBenzinga Japan
BenzingaBenzinga Japan
BenzingaBenzinga Japan
月曜日, 9 14

Ocular Therapeutix Inc

OCULNASDAQ
Trade with Public
Trade with Public
$10.49
-0.13-1.22%
近くで: Sep 11, 5:00 PM EST
$10.69
0.201.91%
時間外: Sep 11, 7:44 PM EST
概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Ocular Therapeutix Financials

Ocular Therapeutix (OCUL) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Ocular Therapeutix Q2 EPS $(0.35) Beats $(0.40) Estimate, Sales $13.475M Beat $13.199M Estimate

Ocular Therapeutix (NASDAQ:OCUL) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.40) by 10.26 percent. This is a 10.26 percent increase over losses of $(0.39) per share
Benzinga Newsdesk

Earnings Scheduled For May 5, 2026

Benzinga Insights

PRO
Ocular Therapeutix Q1 EPS $(0.40) Misses $(0.33) Estimate, Sales $10.785M Miss $12.599M Estimate

Ocular Therapeutix (NASDAQ:OCUL) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.33) by 21.21 percent. This is a 5.26 percent decrease over losses of $(0.38) per share
Benzinga Newsdesk

Stock Market Today: Dow, Nasdaq, S&P 500 Futures Drop— ZIM Integrated Shipping, Masimo, Toll Brothers In Focus (UPDATED)

(Editor’s note: The future prices of benchmark tracking ETFs, the lede, the economic data, and the headline were updated in the story.) U.S. stock futures declined on Tuesday following Friday’s mixed close at the beginning of the holiday-shortened week, as the markets were closed on Monday for Presidents’ Day.
Rishabh Mishra

PRO
Ocular Therapeutix Q4 EPS $(0.29) Beats $(0.32) Estimate, Sales $13.250M Miss $16.128M Estimate

Ocular Therapeutix (NASDAQ:OCUL) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.32) by 9.66 percent. This is unchanged from the same period last year. The company
Benzinga Newsdesk

PRO
Ocular Therapeutix Q3 EPS $(0.38) Misses $(0.37) Estimate, Sales $14.544M Miss $14.627M Estimate

Ocular Therapeutix (NASDAQ:OCUL) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.37) by 3.54 percent. This is a 72.73 percent decrease over losses of $(0.22) per share
Benzinga Newsdesk

データとAPI: Benzinga API · 株式ニュースAPI · アナリスト評価API · 企業ロゴAPI

BenzingaBenzinga Japan

ニュース

パートナーシップ

ベンジンガ・グローバル

© 2026 Benzinga | All Rights Reserved